###############################################################################
# FILE: ts_test.ttl                                                            
# DESC: triples to create TS for PhUSE project                                 
# REQ :                                                                        
# SRC :                                                                        
# IN  :                                                                        
# OUT :                                                                        
# NOTE:                                                                        
# TODO:                                                                        
# DATE: 2019-01                                                                
# BY  : KG                                                                     
###############################################################################

@prefix cd01p: <https://w3id.org/phuse/cd01p#> .              
@prefix cdiscpilot01: <https://w3id.org/phuse/cdiscpilot01#> .
@prefix code: <https://w3id.org/phuse/code#> .                
@prefix custom: <https://w3id.org/phuse/custom#> .            
@prefix owl: <http://www.w3.org/2002/07/owl#> .               
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .       
@prefix sdtmterm: <https://w3id.org/phuse/sdtmterm#> .        
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .        
@prefix study: <https://w3id.org/phuse/study#> .              
@prefix time: <http://www.w3.org/2006/time#> .                
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .            
@prefix prot: <https://w3id.org/phuse/prot_test#> .            



prot:Study_CDISCPILOT01
   rdf:type                                      study:Study;
   skos:prefLabel                                "Study: CDISCPILOT01"^^xsd:string ;
   study:hasPopulation                           prot:EnrolledPopulation_CDISCPILOT01;
   study:hasPopulation                           prot:StudyPopulation_CDISCPILOT01;
   study:adaptiveDesign                          sdtmterm:NoYesResponse_N ;
   study:isAddOnStudy                            sdtmterm:NoYesResponse_N ;
   study:hasProtocolSpecifiedActivity            prot:AdminActivity_DataCutoff_CDISCPILOT01_1 ;
   study:interventionModel                       sdtmterm:InterventionModel_PARALLEL    ;
   study:interventionType                        sdtmterm:InterventionType_DRUG;
   study:narms                                   3 ;
   study:hasPrimObjective                        prot:PrimaryObjective_CDISCPILOT01_1 ;
   study:hasPrimObjective                        prot:PrimaryObjective_CDISCPILOT01_2 ;
   study:hasSecObjective                         prot:SecondaryObjective_CDISCPILOT01_1 ;
   study:hasSecObjective                         prot:SecondaryObjective_CDISCPILOT01_2 ;
   study:hasSecObjective                         prot:SecondaryObjective_CDISCPILOT01_3 ;
   study:hasSecObjective                         prot:SecondaryObjective_CDISCPILOT01_4 ;
   study:randomizedTrial                         sdtmterm:NoYesResponse_Y ;
   study:sexGroup                                sdtmterm:SexGroup_BOTH;
   study:studyType                               sdtmterm:StudyType_INT;
   study:blinding                                sdtmterm:TrialBlindingSchema_DOUBLE_BLIND;
   study:controlType                             sdtmterm:ControlType_PLACEBO;
   study:trialPhase                              sdtmterm:TrialPhase_PHASE2 ;
   study:studyDrug                               code:Substance_xanomeline                                                                             ;
   study:trialType                               sdtmterm:TrialType_SAF  ;
   study:trialType                               sdtmterm:TrialType_EFF  ;
   study:trialType                               sdtmterm:TrialType_PK   ;
.


prot:EnrolledPopulation_CDISCPILOT01
   rdf:type                                      study:EnrolledPopulation;
   skos:prefLabel                                "Enrolled population CDISCPILOT01 ";
.

prot:StudyPopulation_CDISCPILOT01
   rdf:type                                      study:CompletePopulation;
   skos:prefLabel                                "Study population CDISCPILOT01 ";
.

prot:EnrolledPopulation_CDISCPILOT01             study:actualPopulationSize              254 ;.

prot:AdminActivity_DataCutoff_CDISCPILOT01_1
   rdf:type                                      study:DataCutoff;
   skos:prefLabel                                "Interim Analysis Data Cutoff Date ";
   study:hasDate                                 prot:DataCutoffDate_2015-03-31 ;
.

prot:DataCutoffDate_2015-03-31
   rdf:type                                      study:DataCutoffDate;
   skos:prefLabel                                "Interim Analysis Data Cutoff Date";
   code:hasCodeSystem                            code:CodeSystem_ISO8601;
   study:dateTimeInXSDString                     "2015-03-31";
.

prot:PrimaryObjective_CDISCPILOT01_1
   rdf:type                                      study:PrimaryObjective ;
   skos:prefLabel                                "To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]) ";
   study:seq                                     "1 "^^xsd:float;
.

prot:PrimaryObjective_CDISCPILOT01_2
   rdf:type                                      study:PrimaryObjective ;
   skos:prefLabel                                "To document the safety profile of the xanomeline TTS. ";
   study:seq                                     "2 "^^xsd:float;
.

prot:SecondaryObjective_CDISCPILOT01_1
   rdf:type                                      study:SecondaryObjective;
   skos:prefLabel                                "To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas. ";
   study:seq                                     "1 "^^xsd:float;
.

prot:SecondaryObjective_CDISCPILOT01_2
   rdf:type                                      study:SecondaryObjective;
   skos:prefLabel                                "To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas. ";
   study:seq                                     "2 "^^xsd:float;
.

prot:SecondaryObjective_CDISCPILOT01_3
   rdf:type                                      study:SecondaryObjective;
   skos:prefLabel                                "To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The ADAS-Cog (14) will be used for this assessment. ";
   study:seq                                     "3 "^^xsd:float;
.

prot:SecondaryObjective_CDISCPILOT01_4
   rdf:type                                      study:SecondaryObjective;
   skos:prefLabel                                "To assess the treatment response as a function of Apo E genotype. ";
   study:seq                                     "4 "^^xsd:float;
.

prot:EnrolledPopulation_CDISCPILOT01             study:plannedPopulationSize             300 ;.

prot:Study_CDISCPILOT01                          study:hasTitle                          prot:Title_CDISCPILOT01;.

prot:Title_CDISCPILOT01
   rdf:type                                      study:Title;
   skos:prefLabel                                "Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease. ";
.

